Castle Biosciences Inc: president & chief executive officer Derek J. Maetzold sold 14,496 shares

What happened

• Derek J. Maetzold, president & chief executive officer and director, exercised options for 8,165 shares at $2.39 on Oct 5, 2026, paying $19,514.
• The filing shows open-market sales of 14,496 shares on Oct 5, 2026 at a weighted-average price of $35.57 for total proceeds of $515,564.
• The filing also reports a derivative disposition of 8,165 shares at $0 on Oct 5, 2026.

Key details

• Transaction date: Oct 5, 2026.
• Exercise price and cost: 8,165 shares exercised at $2.39 for $19,514.
• Sales: 8,580 shares, 3,198 shares and 2,718 shares sold at a weighted-average $35.57 for total $515,564; sales executed in multiple trades at prices ranging from $35.310 to $35.965 (F2).
• Derivative note: a disposal of 8,165 shares at $0 is reported (derivative transaction code M).
• Vesting: the shares subject to the option are fully vested (F13).
• Plan/trust notes: sales were made pursuant to a Rule 10b5-1 plan adopted Jun 2, 2026 (F1). Several holdings are reported as held in related trusts of which the reporting person is trustee or beneficiary (F3–F12).
• Shares owned after the transaction: not specified in the filing excerpt provided.
• Filing date: Oct 7, 2026 (reporting the Oct 5, 2026 transactions).

Why it may matter

• The filing shows an option exercise and same-day open-market sales, with a derivative entry at $0 also reported; the filing therefore documents an exercise and immediate market sales.
• The sales were executed under a Rule 10b5-1 plan and the options were fully vested per the footnotes.
• This filing does not show why the insider traded or why the company acted.